NEW YORK, Jan. 15-Abbott Laboratories and Compugen will work together to create a comprehensive human mRNA database, the two companies said today.
In this deal, Abbott has secured a license to LEADS, Compugen's computational biology platform. Working together, the two companies will use the platform to model genes, mRNA transcripts, and other genomic information. Abbott will use this data and public data from Compugen's Gencarta system to select new drug targets.
Financial details of the deal were not revealed.
For further information, see the press release.